NCT01755195View on ClinicalTrials.gov

Cabozantinib for Adults With Advanced Soft Tissue Sarcoma

PHASE2CompletedINTERVENTIONAL
Enrollment

55

Participants

Timeline

Start Date

January 15, 2013

Primary Completion Date

September 30, 2020

Study Completion Date

September 11, 2023

Conditions
Refractory Soft Tissue Sarcomas
Interventions
DRUG

Cabozantinib

Cabozantinib inhibits multiple receptor tyrosine kinases (RTKs) implicated in tumor growth, metastasis, and angiogenesis, and targets primarily mesenchymal-epithelial transition factor (MET) and vascular endothelial growth factor receptor 2 (VEGFR2).

Trial Locations (1)

20892

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT01755195 - Cabozantinib for Adults With Advanced Soft Tissue Sarcoma | Biotech Hunter | Biotech Hunter